Collaborative Agreement between XtalPi and Dong-A ST in Research and Development for Immunology Therapies
XtalPi and Dong-A ST Collaborate to Accelerate Development of Next-Generation Treatments
Korea's leading pharmaceutical company, Dong-A ST, and AI-driven drug discovery platform pioneer, XtalPi, have joined forces in a significant collaboration. The partnership, based on XtalPi's intelligent and automated drug discovery platform, aims to rapidly discover and rigorously validate novel drug candidates across multiple modalities.
The collaboration will span the entire R&D process, including candidate validation, efficacy and safety testing, and the formulation of preclinical and clinical development strategies. This comprehensive approach is expected to accelerate the development of next-generation treatments for immune and inflammatory diseases.
John Wang, Senior Vice President of Drug Discovery at XtalPi, and Jae-Hong Park, Head of R&D at Dong-A ST, expressed optimism about the collaboration. Both executives see this partnership as a significant expansion of their respective R&D capabilities.
XtalPi's proprietary AI-driven drug discovery platform combines the speed and generative power of AI with the accuracy of its robotic lab-in-the-loop. The integrated workflow spans deep-learning-based molecule design, quantum physics and molecular dynamics simulations, automated chemical synthesis, and experimental validation.
Through this partnership, Dong-A ST aims to strengthen its pipeline in the immunology and inflammation space and expand its R&D scope beyond small molecule therapeutics. The company plans to explore strategies for pipeline expansion and assess commercialization potential through this partnership.
The geographic proximity of the open innovation offices in Boston is expected to contribute to the efficiency of the collaboration. Both Dong-A ST and XtalPi have offices in the city, which will facilitate closer and more efficient collaboration.
The collaboration intends to unlock unique market opportunities and deliver transformative therapies for global patients. The partnership is positioned to translate scientific innovation into competitive precision medicines.
It's worth noting that the search results do not specify the name of the person who leads research and development at Dong-A ST during the cooperation with XtalPi for developing therapeutics for immunological and inflammatory diseases.
The partnership was formalised with the signing of a Memorandum of Understanding (MOU) between the two companies. The collaboration between Dong-A ST and XtalPi is expected to revolutionise the pharmaceutical industry and bring hope to patients suffering from immune and inflammatory diseases worldwide.
